Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda

Blood

Volumn 95, Issue 5, 2000, Pages 1565-1571

  Bulaj, Zaneta J ^a   Phillips, John D ^a   Ajioka, Richard S ^a   Franklin, Michael R ^a   Griffen, Linda M ^a   Guinee, Donald J ^a   Edwards, Corwin Q ^a   Kushner, James P ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ESTROGEN; FERRITIN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; IRON;

ADOLESCENT; ADULT; ALCOHOLISM; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ESTROGEN THERAPY; FEMALE; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS C VIRUS; HEREDITY; HOMOZYGOSITY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SIDEROSIS;

EID: 0034161367     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1565.005k42_1565_1571     Document Type: Article

References (67)

1. Elder GH. Porphyria cutanea tarda. Semin Liver Dis. 1998;18:67-75.
2. th ed. New York, NY: McGraw-Hill; 1995:2103-2160.
3. Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest. 1976;58:1089-1097.
4. Garey JR, Harrison LM, Franklin KF, Metcalf KM, Radisky ES, Kushner JP. Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda. J Clin Invest. 1990;86:1416-1422.
5. McManus JF, Begley CG, Sassa S, Ratnaike S. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood. 1996;88:3589-3600.
6. McManus JF, Begley CG, Sassa S, Ratnaike S. Three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda. Hum Mutat. 1999;13:412.
7. Garey JR, Franklin KF, Brown DA, Harrison LM, Metcalf KM, Kushner JP. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterology. 1993;105:165-169.
8. Elder GH, Urquhart AJ, De Salamanca RE, Munzo JJ, Bonkovsky HL. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet. 1985;2:229-232.
9. Roberts AG, Elder GH, Newcomb RG, de Salamanca RE, Munzo JJ. Heterogeneity of familial porphyria cutanea tarda. J Med Genet 1988;25:669-676.
10. Waldenström J. Studien über Porphyrie. Acta Med Scand. 1937;82(suppl):1-254.
11. Brunsting LA, Mason HL, Aldrich RA. Adult form of chronic porphyria with cutaneous manifestations. JAMA. 1951;146:1207-1212.
12. Uys C, Eales L. The histopathology of the liver in acquired (symptomatic) porphyria. S Afr J Lab Clin Med. 1963;9:190-197.
13. Ippen H. Allgemeinsymptome der späten Hautporphyrie (Porphyria cutanea tarda) als Hinweise für deren Behandlung. Dtsch Med Wochenschr. 1961;86:127-133.
14. Lundvall O, Weinfeld A. Studies of the clinical and metabolic effects of phlebotomy treatment in porphyria cutanea tarda. Acta Med Scand. 1968;184:191-199.
15. Edwards CQ, Griffen LM, Goldgar DE, Skolnick MH, Kushner JP. HLA-linked hemochromatosis alleles in sporadic porphyria cutanea tarda. Gastroenterology. 1989;97:972-981
16. Roberts AG, Whalley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 1997;349:321-323.
17. Roenigk HH Jr, Gottlob ME. Estrogen-induced porphyria cutanea tarda. Report of three cases. Arch Dermatol. 1970;102:260-266.
18. Bonkovsky HL, Poh-Fitzpatrick M. Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 1998;27:1661-1669
19. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335:1799-1805.
20. Bernard PS, Ajioka RS, Kushner JP, Wittwer CT. Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes. Am J Pathol. 1998;153:1055-1061.
21. Straka JG, Kushner JP, Burnham BF. High-performance liquid chromatography of porphyrin esters. Identification of mixed esters generated in sample preparation. Anal Biochem. 1981;111:269-275.
22. Phillips JD, Kushner JP. Measurement of uroporphyrinogen decarboxylase activity. In Mianes MD, Costa LG, Reed DJ, Sassa S, Sipes IG, eds. Current Protocols in Toxicology. New York, NY: John Wiley & Sons, Inc.; 1999:8.4.1-8.4.13.
23. Bowers MA, Aicher LD, Davis HA, Woods JS. Quantitative determination of porphyrins in rat and human urine and evaluation of urinary porphyrin profiles during mercury and lead exposures. J Lab Clin Med. 1992;120:272-281
24. Edwards CQ, Carroll M, Bray P, Cartwright GE. Hereditary hemochromatosis. Diagnosis in siblings and children. N Engl J Med. 1977;297:7-13.
25. Scheuer P, Williams R, Muir A. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol. 1962;84:53-64.
26. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409-1417.
27. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
28. Prophet Statistics: A User's Guide to Statistical Analysis on the PROPHET System. 4.2 ed. Prepared by Bolt Beranek and Newman Inc., Cambridge, MA. Bethesda, MD: The National Institutes of Health; 1994.
29. Edwards CQ. Hemochromatosis. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's Clinical Hematology; Vol 1, 10th ed. Baltimore, MD: Williams & Wilkins; 1999:1056-1070.
30. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis. 1996;22:187-194.
31. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(suppl 1):62S-65S.
32. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-724.
33. Roberts AG, Whatley SD, Nicklin S, et al. The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology. 1997;25:159-161.
34. Sampietro M, Piperno A, Lupica L, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 1998;27:181-184.
35. Barton JC, Sawada-Hirai R, Rothenberg BE. Acton RT. Two Novel Missense Mutations of the HFE Gene (I105Tand G93R) and Identification of the S65C Mutation in Alabama Hemochromatosis Probands. Blood Cells Mol Dis. 1999;25:147-155.
36. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999;93:2502-2505.
37. Waheed A, Parkkila S, Saarnio J, et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci USA. 1999;96:1579-1584.
38. Fleming RE, Migas MC, Zhou X, et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Proc Natl Acad Sci U S A. 1999;96:3143-3148.
39. Roy CN, Penny DM, Feder JN, Enns CA. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem. 1999;274:9022-9028.
40. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology. 1998;27:1695-1699.
41. Sampietro M, Fracanzani AL, Corbetta N, et al. High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda. Ital J Gastroenterol Hepatol. 1997;29:543-547.
42. Lamoril J, Andant C, Bogard C, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology. 1998;27:848-852.
43. Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol. 1998;28:404-409.
44. Malina L, Stransky J, Zdarsky E. Geographical differences in prevalence of hepatitis C virus infection in PCT (porphyria cutanea tarda). Br J Dermatol. 1997;136:291-292.
45. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102:2108-2113.
46. Arber N, Konikoff FM, Moshkowitz M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci. 1994;39:2656-2659.
47. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology. 1997;26(suppl 1):143S-151S.
48. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci. 1998;43:529-533.
49. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-809.
50. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998;27:1717-1722.
51. Valerio LG Jr, Parks T, Petersen DR. Alcohol mediates increases in hepatic and serum nonheme iron stores in a rat model for alcohol-induced liver injury. Alcohol Clin Exp Res. 1996;20:1352-1361.
52. Fletcher LM, Halliday JW, Powell LW. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol. 1999;14:202-214.
53. LeSage GD, Baldus WP, Fairbanks VF, et al. Hemochromatosis: genetic or alcohol-induced? Gastroenterology. 1983;84:1471-1477.
54. Simon M, Bourel M, Genelet B, Fauchet R, Edan G, Brissot P. Idiopathic hemochromatosis and iron overload in alcoholic liver disease: differentiation by HLA phenotype. Gastroenterology. 1077;73:655-658.
55. Mosher W, Pratt W. Contraceptive use in the United States, 1973-88. Advance Data. 1990;182:1-7.
56. Rabin D. Understanding why women won't take HRT. Cont OB/GYN. 1998;43:133-141.
57. Gindhart TD. Liver tumors and oral contraceptives: pathology and pathogenesis. Ann Clin Lab Sci. 1978;8:443-446.
58. Kubo M, Hosteller KY. Metabolic basis of diethylaminoethoxyhexestrol-induced phospholipid fatty liver. Am J Physiol. 1987;252:E375-E379.
59. Zimmerman HJ. Drug-induced chronic hepatic disease. Med Clin North Am. 1979;63:567-582.
60. Lindberg MC. Hepatobiliary complications of oral contraceptives. J Gen Intern Med. 1992;7:199-209.
61. Haberman HF, Rosenberg F, Menon IA. Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens. Can Med Assoc J. 1975;113:653-655.
62. Benedetto AV, Kushner JP, Taylor JS. Porphyria cutanea tarda in three generations of a single family. N Engl J Med. 1978;298:358-362.
63. Schmid R. Cutaneous porphyria in Turkey. N Engl J Med. 1960;263:397-398.
64. Smith AG, Clothier B, Robinson S, et al. Interaction between iron metabolism and 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice with variants of the Ahr gene: a hepatic oxidative mechanism. Mol Pharmacol. 1998;53:52-61.
65. Sinclair PR, Gorman N. Dalton T, et al. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem J. 1998;330:149-153.
66. Franklin MR, Phillips JD, Kushner JP. Cytochrome P450 induction, uroporphyrinogen decarboxylase depression, porphyrin accumulation and excretion, and gender influence in a 3-week rat model of porphyria cutanea tarda. Toxicol Appl Pharmacol. 1997;147:289-299.
67. Chung I, Bresnick E. Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene. Arch Biochem Biophys. 1997;338:220-226.